Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug ...

NEW YORK CITY, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) has received a consensus rating of “Reduce” from the twelve analysts ...

Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Regions Financial Corp. Dep. Pfd. (Rep. 1/40th Non-Cum. Perp. Pfd. Series C)-0.08% Regions Financial Corp. Dep. Pfd. (Rep. 1/40th Perp. Pfd. Series E)-0.67% ...

Fortrea Holdings (FTRE) stock has hit a 52-week low, dropping to $16.53 as the company grapples with a challenging market environment. According to InvestingPro data, the company... Thomas Pike, Chief ...

(FTRE), CLICK HERE TO INQUIRE ABOUT POTENTIALLY ... On this news, Fortrea’s stock price fell $3.47, or 25.1%, to close at $10.38 per share on March 3, 2025, thereby injuring investors.

Labcorp (LH) announced that it has completed the spin-off of Fortrea (FTRE), the newly formed independent Contract Research Organization providing Phase I-IV clinical trial ...